Patients and specimens

A total of 81 patients who were pathologically diagnosed as PDAC were enrolled. PDAC tissues and paired adjacent nontumor tissues were collected. From January 2008 to June 2011, a follow-up was conducted every 3 to 6 months. Inclusion criteria: (1) older than 18 years; (2) pathologically diagnosed with PDAC; (3) both paired cancer and paracancer tissues were obtained; (4) radical pancreaticoduodenectomy (with or without pylorus preservation). Exclusion criteria: (1) undergo neoadjuvant chemotherapy; (2) pathological specimens could not be obtained; (3) refused follow-up. The detailed clinicopathological records and follow-up information were available for all the patients. The diagnosis and staging were based on the 7th edition of the American Joint Committee on Cancer (AJCC). The male-to-female ratio is 50:31. The age of the patients ranges from 35 to 81 years with a mean age of 59.1 ± 10.3 years. Of the 81 cases, 65 died, and the remaining 16 were still alive until the end of the follow-up period. The median time of follow-up was 13.2 months (range 2.0–41.3). The clinicopathological characteristics of PDAC patients are summarized in Table ​Table1.1. This study was approved by the Ethics Committee of Peking Union Medical College Hospital. All the patients enrolled in the present study provided written informed consent.

Relationship between CD58 expression and clinicopathological characteristics in PDAC patients

*p < 0.05